Immutep Ltd
ASX:IMM
Immutep Ltd
ASX:IMM
Price:
0.485 AUD
3.19%
Market Closed
Updated:
May 8, 2024
Immutep Ltd
Operating Income
|
Immutep Ltd
Operating Income Peer Comparison
Comparables:
MSB
CSL
CUV
TLX
PYC
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Operating Income
-AU$46.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-13%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$55.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$3.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Operating Income
AU$50.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$17.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$21.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-17%
|
See Also
What is Immutep Ltd's Operating Income?
Operating Income
-46.9m
AUD
-46.9m
AUD
Based on the financial report for Dec 31, 2023, Immutep Ltd's Operating Income amounts to -46.9m AUD.
What is Immutep Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-13%
-13%
Over the last year, the Operating Income growth was -6%. The average annual Operating Income growth rates for Immutep Ltd have been -29% over the past three years , -24% over the past five years , and -13% over the past ten years .
You don't have any saved screeners yet
